Press Releases

SUGAR LAND, TX -- (MARKET WIRE) -- 12/04/09 -- Researched by Industrial Info Resources (Sugar Land, Texas) -- Consumers Co-operative Refineries Limited (CCRL) (Regina, Saskatchewan) is not letting current market conditions deter it from moving forward with construction of the $1.9 billion expansion project currently under way at its Regina refinery. The project consists of several new unit additions and major revamps to existing units. Construction on the new units began in the summer of 2009, and revamp modifications are expected to begin in the spring of 2010. The entire project will be complete in 2012 and will increase the total output of Saskatchewan's only oil refinery from 100,000 barrels per day (BBL/d) to 130,000 BBL/d.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=153233, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy related markets. For more than 26 years, Industrial Info has provided plant and project opportunity databases, market forecasts, high resolution maps, and daily industry news. For more information, send inquiries to refininggroup@industrialinfo.com or visit us online at www.industrialinfo.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Joe Govreau
713-783-5147

BEIJING, Dec. 4 /PRNewswire-Asia/ -- Huaneng Power International, Inc. (NYSE: HNP; HKEx: 902; SSE: 600011) (hereinafter as "HPI" or the "Company") announced that an ultra-supercritical coal-fired generating unit (unit 2) with a capacity of 1,036MW of the Phase I Project at Huaneng Haimen Power Plant, which is wholly-owned by the Company, has recently obtained approvals from the relevant authorities and commenced commercial operation in October 2009. To date, the Company's total generation capacity on an equity basis has increased from 40,975 MW to 42,011 MW.

Huaneng Power International, Inc. wholly-owns 18 operating power plants, and has controlling interests in 16 operating power plants and minority interests in 5 operating power companies within China. Such power plants are located in 12 provinces and 4 provincial-level municipalities in China. The Company also has a wholly-owned generation company in Singapore. Currently, the Company is one of China's largest listed power producers with controlled generation capacity of 44,818MW and equity-based generation capacity of 42,011 MW.

    For enquiries, please contact:

     Huaneng Power International, Inc.
     Ms. MENG Jing / Ms. ZHAO Lin
     Tel:   +86-10-6649-1856 / 1866
     Fax:   +86-10-6649-1860
     Email: zqb@hpi.com.cn

     Wonderful Sky Financial Group Limited
     Ms. Katy CHAN / Mr. Ivan KAU / Ms. Gigi CHAN
     Tel:   +852-2851-1038
     Fax:   +852-2815-1352
     Email: katychan@wsfg.hk / ivankau@wsfg.hk / gigichan@wsfg.hk

SOURCE Huaneng Power International, Inc.

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fdc39f/germany_pharmaceut) has announced the addition of the "Germany Pharmaceuticals and Healthcare Report Q1 2010" report to their offering.

Business Monitor International's Germany Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Germany's pharmaceuticals and healthcare industry.

In BMI's Business Environment Ratings (BER) for Q110, Germany rose to pole position, among the nine Western European markets surveyed, having previously been ranked second behind Switzerland. The ratings criteria serve to reinforce the publisher's estimation of the country's potential owing to its strong emphasis on the regulatory environment, despite a major focus on cost-containment and industry-wide dissatisfaction over pricing and reimbursement practices. BMI calculated that Germany's pharmaceutical expenditure was EUR37.4bn (US$55.0bn) in 2008, with the sales of medicines at consumer prices forecast to rise by a compound annual growth rate (CAGR) of only 2.18% in local currency terms to 2014. In 2009 the market value is expected to increase marginally, to reach EUR38.2bn (US$53.7bn), driven by demand rather than pricing considerations. In fact, continued downward pressure on prices can be expected according to the country's industry associations.

Nevertheless, according to a study published in September 2009 by the Institute of Pharmacology at the University of Heidelberg in Germany, patients in Germany pay significantly more for their medicines than those in other European countries. The study attributes the high cost of medicines to the lack of effective price controls, claiming that the mechanisms for authorities and statutory insurance companies to reduce drug prices do not apply when a novel drug is brought into the market. Previous studies have highlighted the imposition of value-added tax (VAT) on pharmaceuticals - in comparison to the VATexempt status of medicines in most other European countries - and prescription volumes as key drivers of increased pharmaceutical spending in the country.

In the light of a difficult economic situation, after a disastrous 2009, the publisher forecasts economic expansion of just 0.9% in 2010, German authorities have continued to implement a variety of cost-containment measures. In September 2009, Germany's healthcare cost-effectiveness regulator IQWIG recommended that health insurers in the country stop reimbursing memantine, an Alzheimer's disease drug, claiming that the drug fails to provide any benefit to patients or caregivers. Since the start of the year, after recommendations by the Federal Joint Committee (G-BA), second opinions by physicians for reimbursable prescriptions of high-cost treatments for pulmonary arterial hypertension (PAH) have been mandatory. BMI believes that, despite only initially being applicable to a small patient group, introducing second opinions to prescriptions will introduce an unnecessary level of bureaucracy to the system, therefore slowing patients' access to essential medicines.

Despite the challenges, the German pharmaceutical marketplace remains a dynamic one. For example, in August 2009, local biopharmaceutical company Apogenix received EUR2.6mn (US$3.6mn) from the federal government to help the company to develop chronic inflammatory disease and oncology candidates. The grant is part of a EUR40mn (US$56.3mn) scheme for businesses in Germany's Rhine- Neckar biotech cluster. In the same month, Belgian pharmaceutical group UCB and Swiss drugmaker Novartis signed a licensing deal for cardiovascular and diabetes products in order to expand in Germany.

Key Topics Covered:

    --  Executive Summary
    --  SWOT Analysis
    --  Pharmaceutical Business Environment Ratings
    --  Germany - Market Summary
    --  Prescription Market Forecast
    --  Competitive Landscape
    --  Company Profiles
    --  Country Snapshot: Germany Demographic Data
    --  BMI Methodology

Companies Mentioned:

    --  GlaxoSmithKline (GSK)
    --  Pfizer
    --  Novartis
    --  Sanofi-Aventis
    --  Merck & Co
    --  Bayer Schering
    --  Boehringer Ingelheim
    --  Stada Arzneimittel

For more information visit http://www.researchandmarkets.com/research/fdc39f/germany_pharmaceut

    Source: Research and Markets

SUGAR LAND, TX -- (MARKET WIRE) -- 12/04/09 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc (NYSE: GSK) (Middlesex, England) has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure. The batch comprised 172,000 doses of the drug and had been distributed to health agencies in the provinces of Alberta, British Columbia, Manitoba, Ontario, Prince Edward Island and Saskatchewan.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=153229, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy related markets. For more than 26 years, Industrial Info has provided plant and project opportunity databases, market forecasts, high resolution maps, and daily industry news. For more information send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Joe Govreau
713-783-5147

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/942000/the_2009_import_an) has announced the addition of the "The 2009 Import and Export Market for Inedible Crude Materials Excluding Fuels in Belgium" report to their offering.

On the demand side, exporters and strategic planners focusing on inedible crude materials excluding fuels in Belgium face a number of questions. Which countries are supplying inedible crude materials excluding fuels to Belgium? How important is Belgium compared to others in terms of the entire global and regional market? How much do the imports of inedible crude materials excluding fuels vary from one country of origin to another in Belgium? On the supply side, Belgium also exports inedible crude materials excluding fuels. Which countries receive the most exports from Belgium? How are these exports concentrated across buyers? What is the value of these exports and which countries are the largest buyers?

This report was created for strategic planners, international marketing executives and import/export managers who are concerned with the market for inedible crude materials excluding fuels in Belgium. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics which appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for inedible crude materials excluding fuels for those countries serving Belgium via exports, or supplying from Belgium via imports. It does so for the current year based on a variety of key historical indicators and econometric models.

In what follows, Chapter 2 begins by summarizing where Belgium fits into the world market for imported and exported inedible crude materials excluding fuels. The total level of imports and exports on a worldwide basis, and those for Belgium in particular, is estimated using a model which aggregates across over 150 key country markets and projects these to the current year. From there, each country represents a percent of the world market. This market is served from a number of competitive countries of origin. Based on both demand- and supply-side dynamics, market shares by country of origin are then calculated across each country market destination. These shares lead to a volume of import and export values for each country and are aggregated to regional and world totals. In doing so, we are able to obtain maximum likelihood estimates of both the value of each market and the share that Belgium is likely to receive this year. From these figures, rankings are calculated to allow managers to prioritize Belgium compared to other major country markets. In this way, all the figures provided in this report are forecasts that can be combined with internal information sources for strategic planning purposes.

After the worldwide summary in Chapter 2 of both imports and exports of inedible crude materials excluding fuels, Chapter 3 goes into detail on imports, but for each major country of origin serving Belgium. A "major" market is defined as a country where Belgium represents a substantially large share of either imports or exports. For each major country exporting to Belgium, one can thus observe how important Belgium is to that exporting country compared to other countries of the world. Chapter 4 does the same, but for exports of inedible crude materials excluding fuels originating from Belgium, for each major country of destination. In doing so, one can discover the share that Belgium has in each major market; this share value is often used as a measure of competitiveness for Belgium. In all cases, the total dollar volume and percentage share values by major trading partner are provided. Combined, Chapters 3 and 4 present a the total picture for imports and exports of inedible crude materials excluding fuels to and from Belgium to and from all other major countries in the world. "Inedible Crude Materials Excluding Fuels" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3).

Key Topics Covered:

1 Introduction And Methodology

2 Belgium And The World Market

3 Imports In Belgium

4 Exports From Belgium

5 Disclaimers, Warrantees, And User Agreement Provisions

For more information visit http://www.researchandmarkets.com/research/942000/the_2009_import_an

    Source: Research and Markets